Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).
Publications
View AllAffiliated Researchers
Institution Info
- Type
- healthcare
- Country
- MY
- Publications
- 1
- Citations
- 0
External Links
Identifiers
- ROR
- https://ror.org/0041bpv82